Yeji
FDA approvalconf 0.85

alixorexton — FDA approval

$ALKS · Alkermes plc. · narcolepsy type 1
Event date
January 6, 2026
151 days ago
Sponsor runway
6 mo
$351.6M liquid

Evidence

“On January 6, 2026, the Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1.”
Source: 8-K filed 2026-01-06View on EDGAR ↗0001193125-26-003453

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

8 insiders · 0 buys · 17 sells
Sell10b5-1
2026-04-06
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
2,034 @ $34.57$70K
Sell10b5-1
2026-04-01
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
9,000 @ $35.51$320K
Exercise10b5-1
2026-04-01
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
5,000 @ $19.34$97K
Sell10b5-1
2026-03-03
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
2,034 @ $29.76$61K
Grant
2026-03-02
Reed Joshua
SVP, Chief Financial Officer
30,854 @ ——
Grant
2026-03-02
POPS RICHARD F
Director and CEO, Alkermes plc
88,843 @ ——
Sell10b5-1
2026-03-02
Parisi Samuel Joseph
VP, Finance (Interim PAO)
6,890 @ $29.29$202K
Grant10b5-1
2026-03-02
Parisi Samuel Joseph
VP, Finance (Interim PAO)
15,033 @ ——
Grant10b5-1
2026-03-02
Parisi Samuel Joseph
VP, Finance (Interim PAO)
14,176 @ ——
Grant10b5-1
2026-03-02
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
36,364 @ ——
Grant10b5-1
2026-03-02
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
78,292 @ ——
Sell10b5-1
2026-03-02
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
2,034 @ $29.29$60K
Sell10b5-1
2026-03-02
Nichols Christian Todd
SVP, Chief Commercial Officer
6,000 @ $30.00$180K
Grant
2026-03-02
Jackson Blair Curtis
EVP, Chief Operating Officer
94,900 @ ——
Grant
2026-03-02
Jackson Blair Curtis
EVP, Chief Operating Officer
44,078 @ ——
Exercise10b5-1
2026-03-02
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
5,000 @ $19.34$97K
Sell10b5-1
2026-03-02
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
9,000 @ $29.72$267K
Grant10b5-1
2026-03-02
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
83,037 @ ——
Grant10b5-1
2026-03-02
Nichols Christian Todd
SVP, Chief Commercial Officer
66,430 @ ——
Grant10b5-1
2026-03-02
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
38,568 @ ——
Grant10b5-1
2026-03-02
Nichols Christian Todd
SVP, Chief Commercial Officer
30,854 @ ——
Grant
2026-03-02
Reed Joshua
SVP, Chief Financial Officer
66,430 @ ——
Exercise
2026-02-26
Parisi Samuel Joseph
VP, Finance (Interim PAO)
2,747 @ ——
Tax
2026-02-26
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
3,049 @ $30.73$94K
Exercise
2026-02-26
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
6,866 @ ——
Tax
2026-02-26
Jackson Blair Curtis
EVP, Chief Operating Officer
3,695 @ $30.73$114K
Exercise
2026-02-26
Jackson Blair Curtis
EVP, Chief Operating Officer
8,322 @ ——
Tax
2026-02-26
Parisi Samuel Joseph
VP, Finance (Interim PAO)
808 @ $30.73$25K
Exercise
2026-02-26
Nichols Christian Todd
SVP, Chief Commercial Officer
5,410 @ ——
Tax
2026-02-26
Nichols Christian Todd
SVP, Chief Commercial Officer
2,403 @ $30.73$74K
Exercise
2026-02-26
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
6,866 @ ——
Tax
2026-02-26
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
3,049 @ $30.73$94K
Tax
2026-02-23
Parisi Samuel Joseph
VP, Finance (Interim PAO)
672 @ $32.19$22K
Exercise
2026-02-23
Parisi Samuel Joseph
VP, Finance (Interim PAO)
2,283 @ ——
Tax
2026-02-23
Nichols Christian Todd
SVP, Chief Commercial Officer
2,845 @ $32.19$92K
Exercise
2026-02-23
Jackson Blair Curtis
EVP, Chief Operating Officer
8,738 @ ——
Tax
2026-02-23
Jackson Blair Curtis
EVP, Chief Operating Officer
3,880 @ $32.19$125K
Exercise
2026-02-23
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
7,689 @ ——
Tax
2026-02-23
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
3,414 @ $32.19$110K
Tax
2026-02-23
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
3,414 @ $32.19$110K
Exercise
2026-02-23
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
7,689 @ ——
Exercise
2026-02-23
Nichols Christian Todd
SVP, Chief Commercial Officer
6,407 @ ——
Tax
2026-02-19
Parisi Samuel Joseph
VP, Finance (Interim PAO)
979 @ $32.00$31K
Exercise
2026-02-19
Nichols Christian Todd
SVP, Chief Commercial Officer
6,045 @ ——
Tax
2026-02-19
Nichols Christian Todd
SVP, Chief Commercial Officer
2,277 @ $32.00$73K
Exercise
2026-02-19
Jackson Blair Curtis
EVP, Chief Operating Officer
9,300 @ ——
Tax
2026-02-19
Jackson Blair Curtis
EVP, Chief Operating Officer
4,130 @ $32.00$132K
Exercise
2026-02-19
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
7,673 @ ——
Tax
2026-02-19
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
3,407 @ $32.00$109K
Exercise
2026-02-19
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
7,673 @ ——
+ 40 more
← All catalysts for $ALKS